共 31 条
[1]
Brufani M., Marta M., Pomponi M., Anticholinesterase activity of a new carbamate, heptylphysostigmine, in view of its use in patients with Alzheimer-type dementia, Eur J Bio-Chem, 157, pp. 115-120, (1986)
[2]
De Sarno P., Pomponi M., Giacobini E., Tang X.C., Williams E., The effect of heptyl-physostigmine, a new cholinesterase inhibitor, on the central cholinergic system of the rat, Neuro-Chem Res, 14, pp. 971-977, (1989)
[3]
Brufani M., Castellano C., Marta M., Et al., A long-lasting cholinesterase inhibitor affecting neural and behavioral processes, Pharm Biochem Behav, 26, pp. 625-629, (1987)
[4]
Perry E.K., The cholinergic hypothesis—ten years on, Br Med Bull, 42, pp. 63-69, (1986)
[5]
Mohs R.C., Davis B.M., Johns C.A., Oral physostigmine treatment of patients with Alzheimer’s disease, Am J Psychiatry, 142, pp. 28-33, (1985)
[6]
Thai L.J., Physostigmine in Alzheimer’s disease, Cholinergic Basis for Alzheimer's therapy, pp. 209-215, (1991)
[7]
Becker R.E., Moriearty P., Unni L., The second generation of cholinesterase inhibitors: Clinical and pharmacological effects, Cholinergic Basis for Alzheimer’s Therapy, pp. 263-296, (1991)
[8]
Herold M.L., Constanzer M.L., Matuszewski B.K., Determination of picogram levels of heptylphysostigmine in human plasma using high-performance liquid chromatography with fluorescence detection, J Chromatogr, 581, pp. 227-236, (1992)
[9]
Zecca L., Radice D., Mosca A., Pagella P.G., Determination of heptylphysostigmine in plasma by high-performance liquid chromatography with electrochemical detection, J Chromatogr Biomed Appl, 615, pp. 169-173, (1993)
[10]
Luzzana M., Dossi G., Mosca A., Measurement of glucose in plasma by a differential pH technique, Clin Chem, 29, pp. 80-85, (1983)